Back to results
US 2023/0348362 A1Published application
Lipid compounds and lipid nanoparticle compositions
AssigneeSuzhou Abogen Biosciences Co., Ltd.
InventorsBo YING, Xiulian WANG
Life of this patent
Estimating the term…
Abstract
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.
Claims31
A compound of Formula (I):
- or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
- G1 and G2 are each independently a bond, C2-C12 alkylene, or C2-C12 alkenylene, wherein one or more —CH2— in G1 and G2 is optionally replaced by —O—;
- each L1 is independently —OC(═O)R1, —C(═O)OR1, —OC(═O)OR1, —C(═O)R1, —OR1, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc, —NRaC(═O)OR1, —SC(═S)R1, —C(═S)SR1, —C(═S)R1, —CH(OH)R1, —P(═O)(ORb)(ORc), —NRaP(═O)(ORb)(ORc), —(C6-C10 arylene)-R1, -(6- to 10-membered heteroarylene)-R1, -(4- to 8-membered heterocyclylene)-R1, or R1;
- each L2 is independently —OC(═O)R2, —C(═O)OR2, —OC(═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf, —NRdC(═O)OR2, —SC(═S)R2, —C(═S)SR2, —C(═S)R2, —CH(OH)R2, —P(═O)(ORe)(ORf), —NRdP(═O)(ORe)(ORf), —(C6-C10 arylene)-R2, -(6- to 10-membered heteroarylene)-R2, -(4- to 8-membered heterocyclylene)-R2, or R2;
- R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
- Ra, Rb, Rd, and Re are each independently H, C1-C24 alkyl, or C2-C24 alkenyl;
- Rc and Rf are each independently C1-C24 alkyl or C2-C24 alkenyl;
- G3 is C2-C12 alkylene or C2-C12 alkenylene, wherein part or all of alkylene or alkenylene is optionally replaced by C3-C8 cycloalkylene, C3-C8 cycloalkenylene, C3-C8 cycloalkynylene, 4- to 8-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene;
- R3 is hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkynyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
- or R3, G1 or part of G1, together with the nitrogen to which they are attached form a cyclic moiety;
- or R3, G3 or part of G3, together with the nitrogen to which they are attached form a cyclic moiety;
- R4 is C1-C12 alkyl or C3-C8 cycloalkyl;
- x is 0, 1, or 2;
- n is 1 or 2;
- m is 1 or 2;
- and
- wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, cycloalkynylene, heterocyclylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
14 more elements
(canceled)
5-7. (canceled)
(canceled)
(canceled)
(canceled)
22-29. (canceled)
A compound in Table 1 or Table 1A, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
A compound of Formula (X):
- or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
- G1 is a bond, C2-C12 alkylene, or C2-C12 alkenylene;
- each L1 is independently —OC(═O)R1, —C(═O)OR1, —OC(═O)OR1, —C(═O)R1, —OR1, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc, —NRaC(═O)OR1, —SC(═S)R1, —C(═S)SR1, —C(═S)R1, —CH(OH)R1, —P(═O)(ORb)(ORc), —(C6-C10 arylene)-R1, -(6- to 10-membered heteroarylene)-R1, or R1;
- R1 is C6-C24 alkyl or C6-C24 alkenyl;
- Ra and Rb are each independently H, C1-C12 alkyl, or C2-C12 alkenyl;
- Rc is C1-C24 alkyl or C2-C24 alkenyl;
- R3 is hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkynyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
- or R3, G1 or part of G1, together with the nitrogen to which they are attached form a cyclic moiety;
- x is 0, 1, or 2;
- n is 1 or 2;
- and
- Z is —OH or halogen;
- wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, cycloalkynylene, heterocyclylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
10 more elements
33-49. (canceled)
Dependencies are inferred from the claim text.